Zotiraciclib

A cyclin-dependent kinase inhibitor

Zotiraciclib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem	12345678
DrugBank
ChemSpider	12345678
KEGG

Zotiraciclib is an investigational cyclin-dependent kinase (CDK) inhibitor that has been studied for its potential use in the treatment of various types of cancer. It is known by its research code TG02.

Mechanism of Action

Zotiraciclib functions by inhibiting multiple cyclin-dependent kinases, which are enzymes that play a crucial role in the regulation of the cell cycle. By inhibiting these kinases, zotiraciclib can induce cell cycle arrest and promote apoptosis in cancer cells. This mechanism is particularly effective in rapidly dividing cells, such as those found in tumors.

Clinical Development

Zotiraciclib has been evaluated in several clinical trials to assess its efficacy and safety in treating different types of cancer, including glioblastoma and other solid tumors. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to cross the blood-brain barrier and target brain tumors effectively.

Pharmacokinetics

The pharmacokinetic profile of zotiraciclib includes its absorption, distribution, metabolism, and excretion. The drug is administered orally and has been shown to have a favorable bioavailability. It is metabolized primarily in the liver and excreted through the kidneys.

Side Effects

As with many cancer therapies, zotiraciclib can cause a range of side effects. Common adverse effects observed in clinical trials include nausea, fatigue, and hematological toxicity, such as neutropenia and thrombocytopenia.

Research and Future Directions

Ongoing research is focused on optimizing the dosing regimen of zotiraciclib and exploring its use in combination with other anticancer agents. Studies are also investigating biomarkers that may predict response to treatment, which could help tailor therapy to individual patients.

Related pages

• Cyclin-dependent kinase
• Cancer treatment
• Glioblastoma
• Apoptosis